Bull case
Connect Biopharma Hldgs is positioned favorably because rademikibart has shown differentiated, statistically significant efficacy in acute COPD, including an 81% reduction in treatment failure, an 85% reduction in new moderate/severe exacerbations, and a 100% reduction in hospital/ED returns, all while maintaining a favorable safety profile. The data also support a credible acute asthma pathway, with a 130-mL placebo-adjusted Day 7 FEV1 benefit in asthma and meaningful treatment-failure improvement despite low placebo event rates, suggesting the drug’s activity is not confined to one indication. With the market capitalization at roughly $70M and external validation from OBERON/TITANIA showing meaningful COPD event reductions without large FEV1 effects, the stock appears to be underappreciating the company’s clinical upside and potential registrational flexibility.